Background
==========

Despite extensive diagnostic evaluation and numerous treatment guidelines \[[@B1]-[@B3]\], a subgroup of chronic cough patients in whom a diagnosis cannot be made even after thorough systematic investigation remain troubled by chronic idiopathic cough (CIC) \[[@B4],[@B5]\], defined as an uncontrollable cough that is difficult to treat. Therefore, there is a great deal of research interest \[[@B6],[@B7]\] regarding the identification of novel antitussive drugs \[[@B8]-[@B11]\] and the establishment of novel therapeutic strategies.

We recently encountered a cluster of patients with allergic fungal cough (AFC), which is intractable and is characterized by sensitization to *Bjerkandera adusta*\[[@B9]\], among a new clinical disease concept termed fungus-associated chronic cough (FACC) \[[@B10]\] with the following manifestations: (1) chronic cough; (2) the presence of environmental fungi, particularly basidiomycetous (BM) fungi, in the sputum; and (3) good clinical response to antifungal drugs. Thus antifungal drugs have provided a new treatment strategy for chronic intractable cough \[[@B11]\], included in unexplained chronic cough \[[@B12]\]; however, the efficacy of anti-fungal therapy for CIC has not been evaluated yet.

As the presence of BM fungi in induced sputum has been shown to be an important factor in distinguishing the clinical manifestations of CIC from those of non-CIC \[[@B13]\], we describe here our clinical experience in 10 CIC patients treated with low-dose itraconazole (ITCZ). We attempted to clarify the problems raised in the process of evaluating the clinical efficacy of low-dose ITCZ, especially with regard to both colonization of BM fungi and sensitization to *B. adusta*.

Case presentation
=================

Methods
-------

Mycological study
-----------------

### Strains and DNA preparation

The sputum samples obtained from the patients with CIC patients were cultured on Sabouraud's dextrose agar (SDA) containing chloramphenicol. The morphological features of the strains were observed with the slide culture method (30°C for 2\~3 weeks). When the white colonies grew widely on SDA; the resulting colonies were moved onto CHROMagar® Candida spread with micafungin sodium (Funguard®, 30 μ/plate) \[[@B11]\].

Allergological tests
--------------------

### Preparation of the antigenic solution

The antigens *Aspergillus, Alternaria, and Candida* were commercially available (Torii Pharmacy, Tokyo, Japan). One liter of Sabouraud dextrose broth in 3 L flasks was sterilized by autoclaving at 121°C for 20 min. Five milliliters of *B. adusta* (NBRC 4983) or *Schizophyllum commune* spore suspension (10^5^ spores/ml) in sterile physiological saline from 14 day-old SDA culture was used to inoculate the flask. The flasks were shaken at 150 rpm in a 25°C rotary shaker incubator. The supernatant was then dialyzed against 5 mM ammonium bicarbonate and lyophilized.

### Intradermal skin test

An antigenic solution (polysaccharide) was injected intradermally with a tuberculin syringe (0.02 mL, 1 mg/mL) to assess the skin response to the solution. The results were judged to be positive when the longer axis of the flare exceeded 9 mm and/or ≥ 3 mm above negative control at 15 min (immediate phase), and 10 mm at 8 h (late phase) after the injection.

### Serological test

House-dust, mite, *Aspergillus, Alternaria, Penicillium, Cladosporium, Candida Trichophyton;* Allergen-specific IgE antibodies were detected using a capsulated hydrophilic carrier polymer radioallergosorbent test fluoroenzyme immunoassay (Phadia, Uppsala, Sweden) at an external laboratory (SRL, Tokyo, Japan).

### Lymphocyte stimulation test

The lymphocyte stimulation test (LST) \[[@B14]\] was performed using the antigenic solution with the Lymphoprep system. The results were considered positive when the magnitude of the response to *B.adusta* was beyond 200% in comparison to the controls using PHA.

Diagnostic criteria of CIC
--------------------------

According to the Japanese Cough Research Society \[[@B1]\], Japanese Respiratory Society \[[@B2]\], and the American College of Chest Physicians evidence-based practice guidelines \[[@B3]\], the cause of chronic cough in each patient was diagnosed based on a questionnaire, blood examination findings, chest and sinus X-rays, induced-sputum examination, pulmonary function tests \[[@B15]\], test for cough reflex sensitivity to inhaled capsaicin \[[@B16]\], bronchial reversibility in response to bronchodilators, bronchial responsiveness to methacholine, and the efficacy of individual cause-specific treatments. The capsaicin cough threshold was defined as the lowest concentration of inhaled capsaicin eliciting five or more coughs (C5). Capsaicin reflex sensitivity was judged to be increased when capsaicin concentration eliciting five or more coughs (C5) was \< 3.9 μM in males or \< 0.98 μM in females \[[@B17]\]. Positive bronchial reversibility was defined as percentage increase in FEV1 \> 12% and absolute increase in FEV1 \> 200 mL. The non-specific bronchial responsiveness to methacholine was assessed according to the method described by Cockcroft et al. \[[@B18]\]. The results were expressed as the provocation concentration (mg/mL) required to cause a 20% or more fall from the baseline FEV1 (respiratory threshold of methacholine; RT-Meth).

The specific treatments given before the diagnosis of CIC was made were as follows: Suspected cough variant asthma \[[@B19]\] was treated in the first instance with β2-agonists (a combination of oral 40 μg/day clenbuterol and 200 μg salbutamol inhalation at bedtime and on demand). If this proved insufficient, treatment was stepped up according to the guidelines on the treatment of asthma. Suspected atopic cough \[[@B20]\], i.e., bronchodilator-resistant cough (eosinophilic tracheobronchitis with cough hypersensitivity), was treated with histamine H1 antagonists and inhaled corticosteroids (a combination of 10 mg/day cetrizine hydrochloride and 400--800 μg/day fluticasone propionate). Suspected sinobronchial syndrome \[[@B21]\] was treated with clarithromycin (oral 200 mg/day). Suspected gastro-oesophageal reflux \[[@B22]\] was treated with a high dose of proton-pomp inhibitors. The duration of each treatment was a minimum of 3 months.

Assessment of treatment efficacy against cough symptoms
-------------------------------------------------------

### Cough Visual Analog Scale (Cough VAS)

A subset of subjects marked a 100-mm linear VAS to indicate severity of their cough from "no cough" to "worst cough." The efficacy of the treatment was evaluated based on the change in the cough scale before and after treatment (Δ cough scale), and a change in Δ cough scale by more than 15 mm was taken to be significant \[[@B23]\].

### Cough-related quality of life

The Leicester Cough Questionnaire (LCQ) \[[@B24]\] is a valid, reproducible, responsive, self-reported, cough-specific health status measure. The Japanese version of LCQ (J-LCQ) was adapted for Japanese conditions following a forward-backward translation procedure \[[@B25]\]. The LCQ total score ranges from 3 to 21 and from 1 to 7 for physical, psychological and social domains; a higher score indicates a better health-related quality of life. The mean (standard deviation) minimal important difference (MID) of the LCQ corresponding to a small change in the four Global Rating of Change Questionnaires (GRCQ) score was 1.3. The MIDs for domains were as follows: physical 0.2, social 0.2, and psychological 0.8 \[[@B26]\].

Protocol
--------

Ten patients diagnosed with CIC and treated for more than 2 years were selected for this study from 1 February to 30 April 2011. Allergological examinations were performed using an antigenic solution of *B. adusta*. The patients received a low dose of ITCZ (50 mg/day) for 14 days as adjunctive therapy. The efficacy of the drug was estimated with use of Cough VAS and the J-LCQ.

IRB approval
------------

This selected, open, single-arm, prospective trial was approved by the institutional review board of Saiseikai Kanazawa Hospital (reference number 2011007) and approval for the study was obtained from UMIN-CTR (reference number R000005872; UMIN000004933). A written informed consent was obtained from each patient prior to enrollment in the study.

Statistical analysis
--------------------

Variables are expressed as the mean (SD) unless otherwise stated. For comparison of multiple groups, analysis of variance (ANOVA) followed by Fisher's protected least significant difference post hoc test was used for parametric data, when a significant difference was found. For nonparametric data, the Kruskal--Wallis test followed by the Mann--Whitney *U* test was applied instead. The *χ*^2^ test was used for categorical data. Analyses were performed using the SPSS statistical software package. In all analyses, *P* \< 0.05 was taken to indicate statistical significance.

Results
=======

Ten patients with CIC had a median age of 65.0 (range, 47--71) years, and 70.0% were female. Chest and sinus radiographs were normal in all patients. Based on their clinical histories, the duration of cough ranged from 27 to 70 months. None of the patients complained of shortness of breath or wheezing and none had post-nasal drip or sinobronchial syndrome that could be responsible for the cough. The mean white blood cell count was 5365.0 ± 1423.6 (SD) μL with 1.8% ± 1.5% (SD) eosinophils in peripheral blood. The total serum IgE levels were found to be elevated in 2 patients and mean level was 132.8 ± 217.9 IU/mL (mean ± SEM). Mean lung functions were as follows: FVC 114.1% ± 21.5% of predicted, FEV1 117.5% ± 26.5% of predicted, and FEV1/FVC ratio 79.7% ± 4.6%. The mean bronchodilator reversibility was 2.1% ± 2.8% (SD). Chronic airflow limitation, defined as the ratio of forced expiratory volume in 1 s (FEV1) to the forced vital capacity (FVC), i.e., FEV1/FVC \< 0.7 and FEV1 \< 80% of the predicted value, and bronchial reversibility in response to bronchodilators were not observed. Bronchial responsiveness to methacholine was heightened in one patient. Cough reflex sensitivity, as assessed by estimation of the capsaicin cough threshold, was increased in 3 patients (Table [1](#T1){ref-type="table"}).

###### 

Characteristics of the 10 patients with CIC

  **Case**            **1**        **2**         **3**         **4**         **5**         **6**        **7**         **8**         **9**         **10**
  ------------------- ------------ ------------- ------------- ------------- ------------- ------------ ------------- ------------- ------------- ------------
  Age (yr)            63           70            68            69            67            55           62            71            47            63
  Gender              M            F             M             F             F             M            F             F             F             F
  Smoking             ex-smoker    never         never         never         never         never        never         never         never         never
  Duration (Month)    49           68            66            70            44            64           48            27            41            62
  WBC                 4350         5800          8100          5600          5900          6600         4000          4900          3000          5400
  Eo (%)              2.4          5.2           1.1           1.7           1.1           0            1.4           1             3.2           1.7
  IgE (IU/ml)         179          20            97            119           734           75.5         16            38            20            29
  FVC                 2.78(81.0)   2.64(118.9)   4.67(137.0)   2.46(108.4)   3.46(149.8)   3.70(98.9)   2.94(126.2)   2.69(123.4)   2.95(110.5)   2.17(87.1)
  FEV1                2.13(80.1)   1.90(118.7)   3.62(138.2)   1.93(114.9)   2.69(152.0)   3.07(96.5)   2.56(143.0)   2.20(144.7)   2.53(106.3)   1.67(80.7)
  FEV1/FVC (%)        76.6         72            77.5          78.5          77.7          83           87.1          81.8          85.8          77
  Reversibility (%)   1.2          2.6           −3.6          5.7           3.7           1.3          0.4           0.9           5.9           2.4
  Rt-Meth (mg/mL)     20000\<      20000\<       20000\<       20000\<       20000\<       20000\<      5000          20000\<       20000\<       20000\<
  Cough (μM)          0.98         31.3          62.5          31.3          1.95          15.6         3.91          0.49          0.49          1.95

Eo: Eosinophil. FEV1: forced expiratory volume in 1 s. FEV1%: the ratio of forced expiratory volume in is (FEV1) to forced vital capacity (FVC). RT-Meth: respiratory threshold of methacholine (mg/ml) required to cause a 20% or more fall in FEV1 from the baseline value. Cough: The capsaicin cough threshold (C5) was defined as the lowest concentration of inhaled capsaicin eliciting five or more coughs.

Positive results of sputum culture for BM, *Aspergillus fumigatus*, *Aspergillus niger*, and *Candida* were detected in 7, 3, 3, and 2 patients, respectively.

The allergological findings of the 10 patients are summarized in Table [2](#T2){ref-type="table"}. Eosinophilia in the induced sputum was observed in 1 patient. Although no immediate cutaneous reactions to *Aspergillus* or *Alternaria* were observed, positive results for immediate cutaneous reaction to *Candida*, *B. adusta*, and *S. commune* were observed in 4, 6, and 1 patient, respectively. In addition, positive results for late cutaneous reaction to *Candida*, *B. adusta*, and *S. commune* were observed in 1, 5, and 1 patient, respectively. Specific IgE for house-dust and mites were positive only in Patient No. 1. Positive ratios on LST against *B. adusta* were observed in 6 patients.

###### 

Allergological findings of the 10 patients with CIC

  **Case**                  **1**       **2**         **3**      **4**         **5**        **6**      **7**       **8**      **9**       **10**
  ------------------ ------ ----------- ------------- ---------- ------------- ------------ ---------- ----------- ---------- ----------- -----------
  Fungal culture            BM, An      Can, Af, BM   Can        BM            BM           none       Af, BM      BM, An     BM          Af, An
  Eo. In sputum             0%          5%            1%         0%            0%           0%         0%          0%         1%          0%
  **Skin tests**                                                                                                                           
  *Aspergillus*      imme   4x4         3x3           2x2/0x0    0x0/0x0       5x6          2x2/0x0    0x0/0x0     2x2/0x0    4x4         4x4
                     late   4x4         4x4           2x3                      5x6          3x3        0x0/0x0     5x5        0x0         3x3
  *Alternaria*       imme   2x2         3x3           4x4        0x0/0x0       2x2          3x3/0x0    0x0/0x0     0x0/3x3    5x5         ND
  *Candida*          imme   5x5         10x10/22x22   0x0/0x0    12x12/16x14   9x10/40x31   4x4/0x0    8x8/28x30   0x0/3x3    ND          ND
                     late   4x4         9x6           5x5                      6x6          3x3/8x8    10x10       0x0/3x3                 
  *B.adusta*         imme   5x6/25x25   4x4/0x0       6x6/0x0    0x0/12x8      0x0/10x8     2x2/0x0    6x6/26x24   0x0/6x6    6x6/16x18   0x0/10x10
                     late   5x5         4x4/10x8      9x8        7x7/10x10     15x14        7x7        15x15       10x10      4x5         4x4
  *S. commune*       imme   0x0/0x0     2x2/0x0       5x5/0x0    0x0/0x0       4x4          4x4/0x0    0x0/0x0     0x0/0x0    4x4         4x9
                     late   0x0/9x9     8x5           8x7        0x0/0x0       7x6          3x3        10x10       3x3        9x9         9x9
  **Specific IgE**                                                                                                                         
  House-dust                1.86        0.34\>        0.34\>     0.34\>        0.34\>       0.34\>     0.34\>      0.34\>     0.34\>      0.34\>
  Mite                      2.69        0.34\>        0.34\>     0.34\>        0.34\>       0.34\>     0.34\>      0.34\>     0.34\>      0.34\>
  *Aspergillus*             0.34\>      0.34\>        0.34\>     0.34\>        0.4          0.34\>     0.34\>      0.34\>     0.34\>      0.34\>
  *Alternaria*              0.34\>      0.34\>        0.34\>     0.34\>        0.34\>       0.34\>     0.34\>      0.34\>     0.34\>      0.34\>
  *Cladosporium*            0.34\>      0.34\>        0.34\>     0.34\>        0.34\>       0.34\>     0.34\>      0.34\>     0.34\>      0.34\>
  *Penicillium*             0.34\>      0.34\>        0.34\>     0.34\>        0.34\>       0.34\>     0.34\>      0.34\>     0.34\>      0.34\>
  *Candida*                 0.34\>      0.34\>        0.34\>     0.34\>        7.05         0.34\>     0.34\>      0.34\>     0.34\>      0.34\>
  *Trichophyton*            0.34\>      0.34\>        0.34\>     0.34\>        0.34\>       0.34\>     0.34\>      0.34\>     0.34\>      0.34\>
  **LST**                   negative    positive      positive   positive      positive     negative   positive    positive   ND          ND

Eo.= eosinophil.

BM; basidiomycetous fungi, Can; *Candida*, Af; *Aspergillus fumigatus*, An; *Aspergillus niger.*

imme; immediate phase response, late; late phase response.

LST; lymphocyte stimulation tests, ND; not done.

The efficacies of low-dose ITCZ therapy in 10 patients are summarized in Table [3](#T3){ref-type="table"}. Significant changes in Δ cough scale or MID in domains of the J-LCQ were observed in 3 and 5 patients, respectively. The Δ cough scale was correlated with changes in some domains of the J-LCQ \[total (r = --0.73, *P* \< 0.05), psychological (r = --0.73, *P* \< 0.05), and social (r = --0.71, *P* \< 0.05)\], but not with changes in the physical domain or in capsaicin cough threshold. There were significant differences in the changes in total score (*P* \< 0.05) and in the social domain (*P* \< 0.05) and Δ cough scale (*P* \< 0.05) between positive and negative results of immediate skin test for *B. adusta*.

###### 

Changes in domains of J-LCQ in 10 patients with CIC pre- and post-low-dose ITCZ therapy

                           **pre-**   **post-**                        **pre-**   **post-**                        **pre-**   **post-**                        **pre-**   **post-**                        **pre-**   **post-**           
  ---------------- ------- ---------- ----------- ------- ---- ------- ---------- ----------- ------- ---- ------- ---------- ----------- ------- ---- ------- ---------- ----------- ------ ---- -------- ---------- ----------- ------ ----
  **Case**         **1**                                       **2**                                       **3**                                       **4**                                      **5**                                   
  J-LCQ                                                                                                                                                                                                                                   
   total                   14.29      15.92       1.63    \*           16.13      16.61       0.48                 18.63      17.61       −1.02                14.84      16.71       1.87   \*            16.71      18.02       1.31   \*
   physical                4.75       6.13        1.38    \*           4.63       5.25        0.62    \*           5.38       5.5         0.12                 5.13       5.5         0.37   \*            5          5.5         0.5    \*
   social                  4.25       4.5         0.25    \*           5.5        5.5         0                    6.25       6.25        0                    5          5.5         0.5    \*            6          6.5         0.5    \*
   psychological           5.29       5.29        0                    6          5.86        −0.14                7          5.86        −1.14                4.71       5.71        1      \*            5.71       6.02        0.31    
  Cough VAS (mm)           30         26          −4      \*           22         24          2                    17         32          15                   10         8           −2                   74         58          −16    \*
  Cough No.                3          4           1                    9          7           −2                   7          8           1                    3          3           0                    6          6           0       
  **Case**         **6**                                       **7**                                       **8**                                       **9**                                      **10**                                  
  J-LCQ                                                                                                                                                                                                                                   
   total                   18.92      16.81       −2.11                17.95      17.52       −0.43                19.59      20.5        0.91                 8.32       12.96       4.64   \*            16.2       20.63       4.43   \*
   physical                6.13       5.63        −0.5                 5.63       5.38        −0.25                6.38       6.5         0.12                 3.25       4           0.75   \*            5.13       6.88        1.75   \*
   social                  6.5        5.75        −0.75                5.75       6           0.25    \*           6.5        7           0.5     \*           2.5        4.25        1.75   \*            5.5        6.75        1.25   \*
   psychological           6.29       5.43        −0.86                6.57       6.14        −0.43                6.71       7           0.29                 2.57       4.71        2.14   \*            5.57       7           1.43   \*
  Cough VAS (mm)           39         44          5                    34         26          −8                   18         30          12                   52         31          −21    \*            61         43          −18    \*
  Cough No.                7          7           0                    4          4           0                    2          9           7       \*           3          4           1                    5          4           −1      

The mean MID of the J-LCQ corresponding to a small change in the four GRCQ score was 1.3. The MIDs for domains were as follows: physical 0.2, social 0.2, and psychological 0.8. A change in △ cough scale by more than 15 mm was taken to be significant. \* Significant improvement in each MID of J-LCQ, Cough VAS after the low dose ITCZ therapy.

In this study, although the efficacy of ITCZ therapy against SMIT was not estimated quantitatively, it was remarkable that such complaints almost disappeared. Positive results for improvement of this SMIT were observed in 6 patients in the BM colonization-positive group (85.7%) and none in the BM colonization-negative group (0%). There was a significant difference in the positive ratio for improvement of this cough-related laryngeal sensation between the two groups.

There were no significant differences in the change in total score or in the domains of LCQ and Δ cough scale between groups with positive and negative results for sputum culture of BM fungi.

Discussion
==========

By focusing on the role of fungal colonization in sensitization of patients with allergic fungal cough \[[@B9]\], it has recently been demonstrated that colonization by *B. adusta* is necessary in the process of sensitization to this fungus \[[@B27]\]. Although the routine use of antifungal drugs against fungus-sensitized asthma or severe asthma with fungus sensitization \[[@B28]\] requires further evaluation, in such cases of FACC or AFC, antifungal therapy is expected to have advantages for reducing or eradicating the colonizing antigen and thus preventing the sensitization process \[[@B9]-[@B12],[@B29]\].

Although the presence of BM fungi in induced sputum has been reported to be an important clinical finding associated with CIC \[[@B13]\], at least three types of association of BM fungi with CIC are possible: 1) sole colonization with BM fungi; 2) sensitization with BM fungi; and 3) colonization and/or sensitization by BM fungi in addition to established CIC. It will be important to perform prospective studies to evaluate both the appropriate dose and period for performing ITCZ therapy in a larger number of CIC patients in the near future. Therefore, it does not seem to be a simple matter to appropriately evaluate the efficacy of antifungal therapy for CIC. A number of problems remain; what should the target of anti-fungal therapy be? How should the efficacy of the proposed antifungal drug be evaluated? The goal of cough therapy is generally considered to be complete remission of cough symptoms. However, even if impossible, it may be a well controlled-state with improvement of cough threshold, cough severity, cough frequency, or quality of life.

In this study, we investigated some important clinical signs \[[@B12]\] or allergological findings to predict the efficacy of antifungal therapy and to clarify some problems raised in the process of evaluating the clinical efficacy of the proposed antifungal drug, especially with regard to both colonization by BM fungi and sensitization to *B. adusta*\[[@B27]\]. The positive ratio of BM cultured from the sputa of 7 CIC patients (70.0%) in the present study was as high as that reported previously (62.5%) \[[@B13]\]. This result reconfirmed the importance of the presence of BM fungi in induced sputum of CIC. The positive high ratio of both skin reaction and LST against *B. adusta* suggested significant correlations with sensitization to this fungus and CIC patients.

*B. adusta* causes "Yakeirotake cough" \[[@B11]\], and has attracted attention because of its potential role in increasing the severity of cough symptoms in FACC patients by sensitization to this fungus. Sautour et al. reported that in outdoor samples, *B. adusta* (8%) was the third most frequent species, especially in summer, and was the third and fourth most common species in the adult hematology unit (13%) and the pediatric hematology unit (11%), respectively, at a French hospital \[[@B30]\]. They also mentioned that the concentration of this fungus was particularly high during the winter 2006/07, with a percentage close to 30% in indoor samples. *B. adusta* is a wood decay BM fungus with a worldwide distribution \[[@B31]\] and therefore this fungal antigen may be a matter of clinical concern.

Based on the mean MID \[[@B26]\] of the J-LCQ \[[@B25]\], the efficacy of low-dose ITCZ therapy was demonstrated in 5 patients. Although the MID may not always reflect sufficient improvement of patient's cough symptoms, it is true that there were significant changes in Cough VAS in 3 of the 5 patients. Therefore, these results do not exclude the possibility of future research on the efficacy of ITCZ therapy in CIC patients. It is also remarkable that changes in Cough VAS were correlated with changes in domains in the J-LCQ.

Despite investigating the allergological pattern with regard to fungal sensitization, none of the allergological findings except positive results for immediate cutaneous reaction against *B. adusta* demonstrated significant correlations with changes in cough VAS or J-LCQ. Appropriate allergological findings, from the aspect of sensitization of *B. adusta*, may lead to success in predicting the efficacy of antifungal therapy in CIC patients.

Although the clinical manifestation, which is represented as a sensation of mucus in the throat \[[@B12]\], has been believed to be an important cough-related laryngeal sensation, it was shown to be correlated with colonization by BM fungi. This small but important symptom may have been overlooked because the symptom is not picked up or reflected even with use of capsaicin cough tests, cough VAS, or LCQ; nevertheless, this symptom and cough itself should also be treated.

Conclusions
===========

At present, it is not possible to conclude whether ITCZ therapy provides sufficient relief in CIC patients. However, this study suggested both the possible applicability of low-dose ITCZ therapy for treatment of CIC patients with regard to BM allergy and the necessity of development of a new assessment questionnaire for cough-related laryngeal sensations.
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